Daraxonrasib (Rasonque) coverage for metastatic pancreatic adenocarcinoma
Customize your policy alerts
Sign up for QualChoice Policy CP.PHAR.794 alerts
Get alerted when Policy CP.PHAR.794 changes without checking for updates manually.
Monitor payer policy activity
This policy governs prior authorization and medical-necessity coverage for Rasonque (daraxonrasib) for QualChoice commercial, HIM/ICHRA, and Medicaid members, primarily for adults with metastatic pancreatic adenocarcinoma who have received prior systemic therapy or are not candidates for multiagent systemic therapy.
The policy was updated after FDA approval to use the diagnosis term pancreatic adenocarcinoma, permit an exception to prior therapy when the provider attests that the member is not a candidate for multiagent systemic therapy, remove prior ECOG performance-status and central-nervous-system-metastasis requirements, and update dosing.
OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.